Literature DB >> 31009826

The non-anticoagulant promise of heparin and its mimetics.

Barbara Mulloy1.   

Abstract

Heparin, the widely used anticoagulant and antithrombotic polysaccharide, has other potential therapeutic uses that arise from its similarity to heparan sulfate. This review provides a brief overview of the most recent developments in this field, paying particular respect to pulmonary and respiratory pharmacology. It has often been said that heparin, with its mimetics and derivatives, shows great promise in the treatment of inflammatory, infectious, and malignant conditions. Difficulties are encountered, however, in translating this promise into worthwhile treatment strategies for patients in some conditions. Several clinical trials of low molecular weight heparins as adjuvant therapy to standard treatment of lung cancers have recently provided no evidence to support the supposed beneficial effects of low molecular weight heparin.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31009826     DOI: 10.1016/j.coph.2019.03.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  8 in total

Review 1.  Neutrophil Elastase and Chronic Lung Disease.

Authors:  Judith A Voynow; Meagan Shinbashi
Journal:  Biomolecules       Date:  2021-07-21

2.  Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.

Authors:  Apparao B Kummarapurugu; Shuo Zheng; Abigail Pulsipher; Justin R Savage; Jonathan Ma; Bruce K Rubin; Thomas P Kennedy; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2021-02       Impact factor: 6.914

3.  Colorectal cancer and cardiovascular disease: A thrombo-inflammatory link?

Authors:  Hugo Ten Cate
Journal:  Eur J Intern Med       Date:  2021-03-26       Impact factor: 4.487

Review 4.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

5.  Elucidating the Binding Mode between Heparin and Inflammatory Cytokines by Molecular Modeling.

Authors:  Mingjia Yu; Tianji Zhang; Jin-Ping Li; Yingxia Tan
Journal:  ChemistryOpen       Date:  2021-10       Impact factor: 2.630

Review 6.  Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

Authors:  Frank M P van Haren; Clive Page; John G Laffey; Antonio Artigas; Marta Camprubi-Rimblas; Quentin Nunes; Roger Smith; Janis Shute; Mary Carroll; Julia Tree; Miles Carroll; Dave Singh; Tom Wilkinson; Barry Dixon
Journal:  Crit Care       Date:  2020-07-22       Impact factor: 9.097

Review 7.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

8.  Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam Coelomactra antiquata.

Authors:  ZhenXing Du; XueJing Jia; Jing Chen; SiYi Zhou; JianPing Chen; XiaoFei Liu; XiaoHuang Cao; SaiYi Zhong; PengZhi Hong
Journal:  Mar Drugs       Date:  2019-12-19       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.